We are proud to announce the USPTO patent covering our 1st Generation micro blood collection device, HemaXis DB, has been fully granted under “Device and Method for Dried Fluid Spot Analysis”. This further secures the market potential for our innovative HemaXis™ platform and the opportunity to leverage its microfluidic based technology. See HemaXis DB in […]
This author has yet to write their bio.Meanwhile lets just say that we are proud shopmanager contributed a whooping 5 entries.
Entries by shopmanager
DBS System announced it closed its Series A at CHF 2.5M which included the direct investment of a Swiss pension fund. DBS System produces blood collection devices that leverage advanced microfluidic technology, greatly simplifying and reducing the cost of blood sampling without modifying existing lab analysis workflows. With this investment, DBS System will industrialize its […]
The DBS System team is proud to announce that Bilan selected us as one of Switzerland’s Top 50 startups out of 156 candidates. It’s recognition that our HemaXis™ blood collection platform is set to revolutionize blood sampling by “Unleashing Labs to Stay Well”. English translation of highlighted content from article segment on DBS System With […]
La fondation collective entame un partenariat inédit avec la plateforme d’investissement zougoise Investiere.ch afin de placer une partie de ses avoirs dans des jeunes pousses. L’argent sera surtout destiné à des entreprises déjà en phase de croissance Le faible engagement des caisses de pension dans le soutien à la création d’entreprises est un sujet de […]
Visit us in the booth of MiniFab, our development and manufacturing partner, to learn more about how HemaXis can help your laboratory leverage the benefits of micro blood sampling. We also invite you to contact Jacob Botta, CSMO at email@example.com to plan a scheduled meeting. MEDICA is the largest medical trade fair in the world. […]
HemaXis DB is a FDA Class 1 medical device. HemaXis DX is in development and for research purposes only. Use of HemaXis devices in Laboratory Developed Tests (LDTs) requires further processing including the establishment of performance characteristics and successful validation by the laboratory in a manner consistent with local regulatory requirements.
By using this website you are agreeing to our Terms and Conditions.